S C Linn
Prospective cost-effectiveness analysis of genomic profiling in breast cancer
Retèl V, Joore M, Drukker C, Bueno-de-Mesquita J, Knauer M, van Tinteren H, Linn S, van Harten W. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. Eur J Cancer 2013; 49:3773-9.
27.08.2013Prospective cost-effectiveness analysis of genomic profiling in breast cancer
27.08.2013Eur J Cancer 2013; 49:3773-9
Retèl V P, Joore M A, Drukker C A, Bueno-de-Mesquita J M, Knauer Michael, van Tinteren H, Linn S C, van Harten W H
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
Drukker C, van de Vijver M, Rutgers E, Sonke G, van 't Veer L, Knauer M, Roumen R, Wesseling J, van Tinteren H, van Harten W, Retèl V, Bueno-de-Mesquita J, Linn S. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. Int J Cancer 2013; 133:929-36.
04.03.2013A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
04.03.2013Int J Cancer 2013; 133:929-36
Drukker C A, van de Vijver M J, Rutgers E J T, Sonke G S, van 't Veer L J, Knauer Michael, Roumen R M H, Wesseling J, van Tinteren H, van Harten W H, Retèl V P, Bueno-de-Mesquita J M, Linn S C
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
Knauer M, Cardoso F, Wesseling J, Bedard P, Linn S, Rutgers E, van 't Veer L. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. Br J Cancer 2010; 103:1788-93.
16.11.2010Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
16.11.2010Br J Cancer 2010; 103:1788-93
Knauer Michael, Cardoso F, Wesseling J, Bedard P L, Linn S C, Rutgers E J T, van 't Veer L J